1. Background {#sec97715}
=============

It is estimated that approximately 170 - 300 million people worldwide are infected with the hepatitis C virus (HCV). The HCV accounts for 20% of all cases with acute viral hepatitis and 70% of all cases with chronic viral hepatitis ([@A25142R1]). The infection with HCV is associated with high morbidity and mortality, due to the development of cirrhosis and hepatocellular carcinoma, and approximately 350000 people die every year, globally, due to HCV infection ([@A25142R2]). The frequencies of HCV genotypes in different geographic regions change over time, depending on the study population, the route of infection, and virus mutation. The HCV genotype 1b is the predominant subtype in Turkey, Russia, Moldova, and Uzbekistan, while genotype 4 is predominant in Saudi Arabia, Iraq, Qatar, Bahrain, Kuwait, and Yemen, and genotype 6a is predominant in China. The HCV genotype 3a is predominant in Pakistan and India. The HCV genotype 1a is the predominant subtype in Iran, despite a high number of visitors from and to Arab countries, in which genotype 4 has been identified as the predominant subtype, and also the fact that Iran has a border with Tajikistan and Turkmenistan in the north, in which genotype 1b appears as the major subtype ([@A25142R3]). Gene sequencing studies identified six major genotypes and more than 100 subtypes of HCV ([@A25142R4], [@A25142R5]). The HCV genotypes 1, 2, and 3 are the most commonly observed genotypes worldwide ([@A25142R6]). The HCV genotype 1b is the most common genotype detected in HCV-infected patients in Turkey ([@A25142R6], [@A25142R7]). The identification of genotypes, prior to therapy, is particularly important, due to the fact that therapies may vary depending on the genotypes involved ([@A25142R2], [@A25142R3]). The distribution of the HCV genotype exhibits geographic variations around the world, and the knowledge of the distribution of genotypes in a particular country, as well as in a particular region of the country, are essential for tailoring appropriate treatment strategies ([@A25142R8]). The studies conducted in Turkey identified HCV genotype 1 as the predominant subtype, and the studies reported a lower frequency for genotype 3. The genotypes identified in Turkey do not exhibit age and gender difference. In contrast to previous reports, the present study showed a prevalence rate for genotype 1 below the average of Turkish data and a prevalence rate for genotype 3 above the average of Turkish data.

2. Objectives {#sec97716}
=============

The aim of the present study was to determine the distribution of HCV genotypes across geographic regions and compare these data with those obtained from other geographic locations.

3. Patients and Methods {#sec97721}
=======================

3.1. Sample Selection {#sec97717}
---------------------

The province of Kahramanmaras is divided into nine districts, with a total population of 1000000. The study hospital is a state hospital and the largest central hospital in the province. Between March 2010 and August 2014, the study included samples from the general population and subjects with the suspicion of illicit drug use, who are placed on probation, during which they are subjected to regular urine drug testing, as mandated by the prosecution office, under the supervision of a psychiatrist, for the purpose of resettlement. At our hospital, HCV RNA and HCV genotypes are regularly tested in samples from HCV-positive patients from the general population and subjects on probation delivered from the city center and nine districts of the province. Accordingly, the presence of HCV RNA was investigated in 2736 samples from anti-HCV positive patients. An HCV genotype analysis was performed in 313 patients with HCV-RNA positivity. The local ethics committee approved the study with an issue number 3, dated May 26, 2015. Informed consent was obtained from the patients who underwent urine drug testing.

3.2. Hepatitis C Virus RNA Analysis {#sec97718}
-----------------------------------

The sera separated from the blood samples dispatched to our laboratory, with the diagnosis of HCV, were stored at -80°C until analysis. The samples were warmed to room temperature before analysis. Viral DNA was extracted using a commercial extraction kit (QIAsymphony DSP Virus/Pathogen Midi Kit, QIAGEN, Hilden, Germany). Quantification of HCV RNA was performed using ArtusHCV QS-RG Q Kit (QIAGEN, Hilden, Germany) and the real-time polymerase chain reaction (RT-PCR) method in the Rotor-Gene RG-Q (QIAGEN, Hilden, Germany) device.

3.3. Genotyping in HCV RNA Positive Serum Samples {#sec97719}
-------------------------------------------------

The HCV genotype was tested using the RT-PCR method as per the manufacturer's instruction. Genotypes 1/2/3/4 were analyzed. Genotyping was performed in serum samples obtained from 313 patients that were found to be positive for HCV-RNA. The sera were stored at -80ºC, until the day of analysis. The samples were warmed to room temperature before analysis. The HCV genotype analysis was performed using GenoSen's HCV Genotyping 1/2/3/4 RT-PCR Reagents Kit (Genome Diagnostics, New Delhi, India). For each reaction, 7.5 μL HCV Genotyping Super Mix (R1) were mixed with 2.5 μL of HCV Genotyping Mg solution (R2) and 15 μL of patient serum. After 10 minutes of a single cycle at 95°C in the Rotor-RG-Q (QIAGEN, Hilden, Germany), 45 cycles were completed (15 sec at 95°C, 20 seconds at 55°C, and 15 seconds at 72°C).

3.4. Urine Drug Test {#sec97720}
--------------------

The presence of amphetamines (i.e. captagon, Ritalin, Dexedrine, and ecstasy), cocaine, opiates (i.e. morphine, codeine, heroin, oxycodone, fentanyl, and methadone) and cannabinoids (THC and cannabis) were investigated in urine samples from patients who were on supervised release. All these tests were performed using Roche/Hitachi Cobas c501 device (Roche/Hitachi, Indianapolis, IN, USA). Amphetamine was tested with an Amphetamines II (AMPS2) kit, cocaine was tested with a Cocaine II (COC2) kit, opiates were tested with an Opiates II (OPI2) kit, and cannabinoids were tested with a Cannabinoids II (THC2) kit ([@A25142R9], [@A25142R10]).

4. Results {#sec97722}
==========

Between March 2010 and May 2014, HCV genotype analysis was performed on a group of 313 patients, which included 212 males (67.7%) and 101 females (32.2%). The mean age of the patients was 41.29 ± 20.32 years. The HCV genotype 1 favored female gender, affecting 56.7% of women, with a mean age of 60.4 years. The HCV genotype 3 favored the male gender, affecting 95.8% of men, and the mean age was 25 years. The age distribution and mean age, according to the genotypes, are presented in [Table 1](#tbl25175){ref-type="table"}. The mean viral load was 1.6 × 10^6^ IU/mL, for genotype 1, and 2.1 × 10^6^ IU/mL, for genotype 3. The mean HCV RNA load of the patients was 1.9 × 10^6^ IU/mL. In terms of HCV genotype distribution, 162 patients (51.7%) had genotype 1, 144 patients (46%) had genotype 3, four patients (1.3%) had genotype 2, and three patients (1%) had genotype 4. As depicted in [Figure 1](#fig18787){ref-type="fig"}, the prevalence of genotype 1 declined and the prevalence of genotype 3 increased over the years. The individuals convicted of illicit drug offenses in Turkey are placed on probation, during which they are subjected to urine drug testing every 3 weeks, as mandated by the prosecution office, under the supervision of police, after providing consent for the test. After the retrospective review of 313 patients, the results of urine drug tests were available in only 65 (20.2%) patients, 61 (93.8%) of which had HCV genotype 3. Other data regarding the patients, except age, gender, and place of origin, could not be obtained. Of patients possessing a risk factor, only 65 had a positive history for illicit drug use.

###### Distribution of Patients According to Gender and Mean Age ^[a](#fn23558){ref-type="table-fn"}^

  Genotype   Sample Size   Mean Age, y           
  ---------- ------------- ------------- ------- -------
  **1**      92 (56.7)     70 (43.2)     60.44   51.43
  **2**      \-            4 (100)       \-      40
  **3**      6 (4.2)       138 (95.8)    31.4    25
  **4**      2 (66.6)      1 (33.3)      24      25

^a^ Data are presented as mean or No. (%).

![The Percent Distribution of Genotype Over the Years](hepatmon-15-04-25142-i001){#fig18787}

5. Discussion {#sec97723}
=============

The HCV genotyping has an important role in the selection of appropriate therapy, duration of treatment, and close monitoring of the response to therapy, in patients with chronic hepatitis C infection. The response to interferon therapy, in patients infected with HCV genotypes 1 and 4, is poorer and the duration of treatment is longer, compared to patients infected with genotypes 2 and 3. In addition, patients infected with genotype 1b have been reported to have a higher risk of developing hepatocellular carcinoma. The HCV genotyping, besides shaping the treatment, also provides information regarding the prognosis of the patients ([@A25142R8]). Of the 313 patients who were found to be positive for HCV RNA, 67.7% were males, who were significantly predominant among these patients (P = 0.0001). Although other studies conducted in Turkey and Pakistan showed no significant difference in terms of gender, the results of the present study showed male predominance, which was parallel to the findings of a study conducted in Iran (79.6%) ([@A25142R11]-[@A25142R13]). When genotype distribution was evaluated in terms of gender, genotype 3 showed 95.8% male predominance and type 1 showed 56.7% female predominance. The mean age of the patients in our study was 41.29 ± 20.32 years. This result was consistent with the findings of Hadinedoushan et al. ([@A25142R13]), who reported an age range of 21 - 31 years for genotype 1a and the predominance of genotype 3 in all age groups, beyond this age group. The mean age was 55 years in 161 patients with genotype 1. This finding was consistent with the finding of Buruk et al. ([@A25142R11]). When the mean age was analyzed separately for each year, the mean age for type 1 was 48 years in 2010, 54 years in 2011, 60 years in 2012, 60 years in 2013, and 62 years in 2014. There was an increase in the mean age, between 2010 and 2014. The mean age was 25 years in 138 patients with genotype 3. There was an increase in the mean age for type 3, when it was analyzed separately for each year. The mean viral load for HCV RNA was 1.9 × 10^6^ IU/mL. There was no significant correlation between viral load for HCV RNA and HCV genotype. Likewise, Hadinedoushan et al. ([@A25142R13]) did not report any relationship between viral load and genotype. The genotype distribution pattern in Turkey shows the predominance of genotype 1 (57.6 - 100%). In general, genotype 1 is more common in the interior regions and it is reported to be less common in large cities and in those allowing the flow of immigrants ([@A25142R7], [@A25142R11], [@A25142R14]-[@A25142R24]). The studies related to HCV genotype distribution in Turkey are presented in [Table 2](#tbl25176){ref-type="table"} [Figure 2](#fig18788){ref-type="fig"}.

###### The Studies Related to HCV Genotype Distribution in Turkey

  Studies in Turkey         Year   Genotypes (%)   Reference                                
  ------------------------- ------ --------------- ----------- ------- ------ ------ ------ ----------------
  **Bozdayi et al.**        2004                   11          84      3      3      1      ([@A25142R14])
  **Selcuk et al.**         2006                   24.6        68.5                  7      ([@A25142R15])
  **Altuglu et al.**        2008                   9.9         87.2    0.9    1.4    0.6    ([@A25142R7])
  **Sanlidag et al.**       2009                   2           90      2             5      ([@A25142R16])
  **Kucukoztas et al.**     2010                   1.9         76.9    3.8    9.6    1.9    ([@A25142R17])
  **Celik et al.**          2010                   8.99        88.20   1.12   1.69          ([@A25142R18])
  **Karsligil et al.**      2011                   9.8         78.4    7.8    2      2      ([@A25142R19])
  **Gokahmetoglu et al.**   2011                   3.4         52.7    2.7    0      35.6   ([@A25142R20])
  **Kayman et al.**         2012                   2.4         57.6    3.2    1      32     ([@A25142R21])
  **Rota et al.**           2013                   3.1         86.3    6.2    2.1    2.1    ([@A25142R22])
  **Buruk et al.**          2013                   5.3         87.5    1.6    4.9    0.7    ([@A25142R11])
  **Tezcan et al.**         2013                   1.7         84.7    0.4    4.2    0.8    ([@A25142R23])
  **Current Study**         2014   51.7                                1.3    46     1      

![Current Data of HCV Genotype Distribution Geographical map of the Cities in Turkey](hepatmon-15-04-25142-g001){#fig18788}

In the present study that was conducted in the province of Kahramanmaras, which has a population of 1 million people and is located in the Mediterranean region, the prevalence of genotype 1 was 51.7% and the prevalence of genotype 3 was 46%, which differed from the country data. Consistent with the data from other regions in Turkey, the prevalence of genotype 2 was 1.3% in the present study. High prevalence rates have been reported for genotype 4, which is mostly reported in the Middle East, in Kayseri and Afyon provinces, in Turkey ([@A25142R21], [@A25142R25]). The prevalence of genotype 4 was found to be 1% in the present study, which is consistent with other studies. The analysis of yearly distribution revealed interesting findings. Genotype 1 was the predominant type in years 2010 and 2011 (76% and 65%, respectively), and this rate declined to 36% and lost its predominance in 2012. The HCV genotype 3 has a low countrywide prevalence in Turkey (1-3%) ([@A25142R7], [@A25142R11], [@A25142R14], [@A25142R16]-[@A25142R19], [@A25142R21]-[@A25142R23]). The highest prevalence rate was reported by Kucukoztas et al. ([@A25142R17]), as 9.6%. Different from the other studies reported in other regions, the prevalence of HCV genotype 3 was 46%, which was a very high prevalence rate that has not been previously reported. When the study data were analyzed separately for each individual year, the 76% prevalence rate for genotype 1 in 2010 declined to 36% in 2013, and, in contrast, the 24% prevalence rate for genotype 3 in 2010 increased to 62% in 2013 and become the predominant genotype. We suggest that intravenous drug use may have become more common among young males, and this may have led to an increase in the prevalence of genotype 3 in Kahramanmaras City. However, further studies are required to confirm the increase in the prevalence. Genotype distribution across years is presented in [Figure 2](#fig18788){ref-type="fig"}. It can be argued that genotype 3 in the southern region of Turkey is becoming more prevalent, when compared to the prevalence rate in other regions. The response to therapy is better in genotype 3, when compared to genotype 1; however, genotype 3 has clinical significance due to its association with hepatosteatosis and accelerated liver fibrosis, in the case of chronic disease, and early therapy is essential for better prognosis ([@A25142R8]). We consider that further studies must be conducted to determine the causes for increasing prevalence of genotype 3 in the southern region of Turkey, which is different from the other regions. In the Turkish justice system, those who are arrested or sentenced to prison for the crimes they have committed can be placed on supervised release within the community, under which the parolee is considered to be serving his/her sentence under custody and supervision, instead of serving prison sentence. In this scope, individuals who are convicted of illicit drug offenses are subjected to urine drug testing every 3 weeks, by the prosecution office, under the supervision of the police, after providing consent ([@A25142R26]). Genotype 3 is more common among intravenous drug users and young people ([@A25142R27]-[@A25142R31]). Based on these data, 313 patients were retrospectively reviewed for the availability of urine drug testing in the scope of supervised release, to investigate the reasons for increased prevalence of genotype 3, which became the predominant type over years. The results of urine drug tests were available in only 65 patients (20.2%). As explained in [Table 3](#tbl25177){ref-type="table"} in detail, 61 of 65 patients (93.8%) had HCV genotype 3. The mean age of the patients with HCV genotype 3 was 25 years and the fact that 95.8% of these patients were males suggested that other patients, for whom urine drug tests were not available, were also illicit drug users. However, this presumption requires support from further comprehensive studies.

###### Distribution of HCV Genotypes and Illicit Drugs Detected in Patients who Have Been Placed on Probation

  Drugs                                                         Type 1   Type 2   Type 3   Type 4
  ------------------------------------------------------------- -------- -------- -------- --------
  **Opiates positive, iv**                                      1        \-       24       \-
  **Cannabinoids/Amphetamines/Cocaine positive, oral**          1        \-       12       \-
  **History of opiates use, iv**                                \-       \-       15       \-
  **History of Cannabinoids/ Amphetamines/Cocaine use, oral**   1        \-       10       1
  **Total**                                                     3                 61       1

The HCV genotypes show different distribution patterns in different parts of the world ([@A25142R32]-[@A25142R35]). Attaullah et al. ([@A25142R12]) examined genotype distribution in 28400 HCV-infected individuals studied in 34 different trials in Pakistan, and reported a prevalence rate of 78.96% for genotype 3, 7.03% for genotype 1, 3.81% for genotype 2, 1.59% for genotype 4, 0.10% for genotype 5, 0.13% for genotype 6, and 5.03% for mixed genotypes. Furthermore, they did not report differences between HCV genotypes, in terms of age and gender. Other studies have also reported findings supporting these results ([@A25142R36]-[@A25142R38]). However, the studies in the US and Asia reported that genotype 3 was associated with young age, particularly with intravenous drug users, tattooing, and piercing. Outbreaks have been reported among intravenous drug users, as a result of shared use of injectors and needles ([@A25142R27]-[@A25142R31], [@A25142R37]). Hadinedoushan et al. ([@A25142R13]) reported a prevalence rate of 50% for HCV genotype 3, 38% for genotype 1a, 6.8% for genotype 1b, and 1.6% for genotype 2. Zhang et al. ([@A25142R39]) studied HCV-infected intravenous drug users in China and reported a prevalence rate of 47% for genotype 6 and 41% for genotype 3. Sanders-Buell et al. ([@A25142R40]) reported a prevalence rate of 62% for genotype 3 and 35% for genotype 1 among HCV-infected intravenous drug users in Afghanistan. The limitation of the present study was that urine drug tests were conducted on only 65 of the 313 patients.

In conclusion, the present study revealed data regarding the distribution of HCV genotypes over a period of 4 years in the province of Kahramanmaras, which is located in the southern part of Turkey. The main difference of the present study from other reports in Turkey is that the prevalence of HCV genotype 1 declined and the prevalence of HCV genotype 3 increased over the years in Turkey, to become the predominant genotype, and the prevalence rate for genotype 3 is the highest rate ever reported for this genotype in the literature.
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